Magical mushroom psilocybin shows five years of depression relief after a single dose, in the study

According to a new study, psilocybin, the main psychoactive ingredient in magical mushrooms, can alleviate depression for at least five years after a single dose.

The study, presented at the Psychedelic Science 2025 Conference in Denver on June 18, followed up with patients diagnosed with it. Clinical depression – Also known as Major Depression Disorder (MDD), she participated in a previous psilocybin treatment study in 2020.

“Most people who took part in our exam reported improvements in the intensity of depression symptoms, or how they experienced depression that lasted up to five years after the exam,” Alan Davis, co-author of Ohio State’s Center for Psychedelic Drug Research and Education, told Fox News Digital.

Psychedelics as potential mental health treatments are being investigated by the Trump administration

Doug Drysdale, CEO of Canadian pharmaceutical company Cybin in Toronto, Ontario, told Fox News Digital that he is talking about Psilocybin and other psychedelic-based treatments in the treatment of MDD and other mental health conditions.

“The results of this study are certainly very encouraging,” said Drysdale, who was not involved in the study.

Previous studies have pointed out the possibility of psilocybin Potential antidepressantsurged researchers to conduct their first randomized clinical trial.

The first 2020 trial published in Jama Psychiatry included 24 patients Major depressive disorder. Half received psilocybin at the start of the trial, and the other half received treatment eight weeks later.

Each patient also received 11 hours of psychotherapy.

What is ketamine therapy? Mormon’s reality promotes controversial treatment

One month after treatment, 17 patients reported experiencing symptoms relief. According to a published study, 14 people reported complete remission from depression.

“The efficacy of psilocybin therapy after a single or several doses represents another substantial advantage over commonly used antidepressants that require daily administration,” the researchers wrote.

The new study aims to refer to the long-term effects of this treatment to the original at 21. Trial participants.

67% reported remission from depression five years after treatment, and they also had one. There’s less anxiety And it’s easier to function every day.

“This study does not account for the naturalistic changes that may have affected depression in five years since the major trial.”

For those who have returned depression, many still report lasting benefits in their attitudes, perspectives, and the ability to pursue what is meaningful to them, Davis told Fox News Digital.

“It certainly requires more controlled and rigorous research, but at least anecdote, these findings are very interesting and I am cautiously optimistic about the potential dilated effects offered by these types of treatment,” added Drysdale.

Other factors may also play a role in participants’ long-term Benefits of mental healthpsychotherapy sessions and other antidepressants agreed.

“This study does not account for the naturalistic changes that may have affected depression in the five years since the main trial. The sample does not represent a population of people suffering from depression,” Davis told Fox News Digital.

Parkinson’s patients taking “magic mushrooms” see important benefits, research finds

Psilocybin is also being investigated as a potential treatment Postmolecular depression (PPD), one in seven new mothers affects.

A 2022 study outlined the potential role of psychedelics in PPD cases and found that psilocybin was shown to catalyze the sensation of “reconnection” in new mothers.

Click here to sign up for our health newsletter

“This effect in PPD may allow for improved mood and maternal sensitivity to infants by promoting a maternal sense of ‘reconnection’, and may have a positive effect on maternal satisfaction and maternal relationships,” the researchers said.

In February, Cleveland Clinic reported on future studies investigating single-dose psilocybin as a method of treating PPD.

The current second stage trial focuses on Re104, a unique drug similar to psilocybin.

Study participants will undergo multiple physical and mental health tests.

Potential risks and limitations

Ryan Moss, chief science officer at Filament Health, a Canadian clinical stage natural psychedelic drug developer, emphasized the importance of administering psychedelics in a safe environment when treating. Mental health status.

Visit us for more health articles www.foxnews.com/health

“Psychedelic experiences can be characterized by anxiety, hallucinations and delusions,” Moss previously told Fox News Digital.

Experts recommend that the therapeutic use of psychedelics must be carefully managed by healthcare professionals.

“Some patients who use traditional psychedelics have had adverse experiences, some patients have Cardiovascular events Under clinical trials. ”

To mitigate these risks, Moss recommended participants in clinical trials who received thorough preparation and monitoring by trained experts during the session.

Dr. Marc Siegel, Professor of Clinical Medicine Nyu Langone Medical Center Senior medical analysts at Fox News previously interviewed two top psychedelic researchers. Dr. Charles Marmar, founder and founder of Psychedelic Psychotherapy and Mount Sinai in New York and director of Nyu Langone’s PTSD Research Program.

Click here to get the Fox News app

“They agree that there is a potential for treatment if they are being studied very carefully under very strict medical guidance, but there are major downsides when it comes to unregulated recreational uses,” Siegel told Fox News Digital at the time.

“Both physicians are likely to see therapeutic value for psychedelics when carefully managed. Medical professionals“Siegel added.

Melissa Rudy and Angelica Stabile of Fox News Digital contributed to the report.